Kohjin Bio Co Ltd

Kohjin Bio maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.74, indicating moderate leverage. The company holds JPY 1.73 billion in cash and equivalents, but this is offset by JPY 2.47 billion in long-term debt, resulting in a net cash position of negative JPY 743 million. The current ratio of 1.42 suggests the company has sufficient short-term assets to cover its liabilities, though the liquidity risk is assessed as medium.

Profitability metrics show a return on equity (ROE) of 5.32% and a return on assets (ROA) of 2.7%, both below the industry median for biotechnology firms. Operating income of JPY 225.85 million and net income of JPY 177.84 million reflect a healthy gross margin of 46.6%, but the company's profitability is constrained by high R&D and capital expenditures.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in Japan. No material revenue is attributed to international operations, and the company does not report segment-specific performance metrics.

Looking ahead, Kohjin Bio is projected to maintain stable revenue growth, with a modest increase in the current fiscal year and a continuation of this trend in the next fiscal year. The company's capital expenditures are expected to remain high, driven by ongoing R&D and production facility investments. However, the company's operating cash flow of JPY 823.68 million provides a buffer against near-term liquidity pressures.

The risk assessment highlights a medium liquidity risk and a low dilution risk. The company has not issued additional shares in the past year, and there are no indications of imminent equity dilution. However, the negative net cash position and high long-term debt could pose challenges if cash flow from operations declines. No recent regulatory or legal events have been reported that would significantly impact the company's operations.

Recent filings and transcripts indicate that the company is focused on expanding its pipeline of biopharmaceutical products and advancing clinical trials for several key candidates. No major strategic shifts or partnerships have been disclosed in the latest reports.

Net income surged 106.4% year-over-year to JPY 795 million, demonstrating strong recent earnings growth.

Cash conversion ratio of 4.63 ranks best-in-class compared to the 0.95 cohort median.

Revenue grew 9.1% year-over-year to JPY 5.2 billion, reflecting consistent top-line expansion.

Debt-to-equity ratio of 0.74 is in the bottom quartile, indicating higher leverage than peers.

Medium liquidity risk flags suggest potential challenges in meeting short-term financial obligations.

Medium credit risk indicates potential concerns regarding the company's ability to service its debt.

Revenue ¥1.29B, −9,1% YoY; Operating income −56,0% YoY.

• ▍Revenue ¥1.29B, −9,1% YoY
• ▍Operating income −56,0% YoY
• ▍Net income −67,6% YoY
• ▍Net margin 6.0%

Revenue ¥1.28B, +1,5% YoY; Operating income +5,8% YoY.

• ▍Revenue ¥1.28B, +1,5% YoY
• ▍Operating income +5,8% YoY
• ▍Net income +4,6% YoY
• ▍Net margin 9.3%

Revenue ¥1.22B, −1,8% YoY; Operating income −36,6% YoY.

• ▍Revenue ¥1.22B, −1,8% YoY
• ▍Operating income −36,6% YoY
• ▍Net income −49,4% YoY
• ▍Net margin 6.7%